124 related articles for article (PubMed ID: 37914142)
21. Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial.
Baker S; Lechner L; Liu M; Chang JS; Cruz-Lim EM; Mou B; Jiang W; Bergman A; Schellenberg D; Alexander A; Berrang T; Bang A; Chng N; Matthews Q; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresne S; Arbour G; Yu I; Tyldesley S; Olson RA
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1497-1506. PubMed ID: 38220069
[TBL] [Abstract][Full Text] [Related]
22. Surgery or radiotherapy for stage I lung cancer? An intention-to-treat analysis.
Spencer KL; Kennedy MPT; Lummis KL; Ellames DAB; Snee M; Brunelli A; Franks K; Callister MEJ
Eur Respir J; 2019 Jun; 53(6):. PubMed ID: 30635294
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic body radiotherapy for metastatic sarcoma to the lung: adding to the arsenal of local therapy.
Gutkin PM; Gore E; Charlson J; Neilson JC; Johnstone C; King DM; Hackbarth DA; Wooldridge A; Mannem R; Bedi M
Radiat Oncol; 2023 Mar; 18(1):42. PubMed ID: 36859309
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.
Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159
[TBL] [Abstract][Full Text] [Related]
25. The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review.
Le Guevelou J; Sargos P; Siva S; Ploussard G; Ost P; Gillessen S; Zilli T
Eur Urol Focus; 2023 Jan; 9(1):114-124. PubMed ID: 36151031
[TBL] [Abstract][Full Text] [Related]
26. Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma.
Chudgar NP; Brennan MF; Munhoz RR; Bucciarelli PR; Tan KS; D'Angelo SP; Bains MS; Bott M; Huang J; Park BJ; Rusch VW; Adusumilli PS; Tap WD; Singer S; Jones DR
J Thorac Cardiovasc Surg; 2017 Jul; 154(1):319-330.e1. PubMed ID: 28395901
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Lindner LH; Litière S; Sleijfer S; Benson C; Italiano A; Kasper B; Messiou C; Gelderblom H; Wardelmann E; Le Cesne A; Blay JY; Marreaud S; Hindi N; Desar IME; Gronchi A; van der Graaf WTA
Int J Cancer; 2018 Jun; 142(12):2610-2620. PubMed ID: 29383713
[TBL] [Abstract][Full Text] [Related]
28. Impact of Consolidative Radiation on Overall and Progression-Free Survival in Pediatric, Adolescent, and Young Adult Metastatic Bone and Soft Tissue Sarcoma.
Chang L; D'Amiano A; Bhatia R; Yenokyan G; Llosa NJ; Ladle BH; Meyer CF; Levin AS; Pratilas CA; Ladra M; Acharya S
Int J Radiat Oncol Biol Phys; 2024 Feb; 118(2):474-484. PubMed ID: 37797747
[TBL] [Abstract][Full Text] [Related]
29. The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma.
Franzese C; Marini B; Baldaccini D; Badalamenti M; Navarria P; Bellu L; Franceschini D; Comito T; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Lo Faro L; Tomatis S; Scorsetti M
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4411-4417. PubMed ID: 36109401
[TBL] [Abstract][Full Text] [Related]
30. Patterns of Recurrence and Survival after Surgery or Stereotactic Radiotherapy for Early Stage NSCLC.
van den Berg LL; Klinkenberg TJ; Groen HJM; Widder J
J Thorac Oncol; 2015 May; 10(5):826-831. PubMed ID: 25629639
[TBL] [Abstract][Full Text] [Related]
31. Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer.
Mercier C; Claessens M; De Troyer B; Debacker T; Fransis K; Vandeursen H; Ost P; Dirix P
Front Oncol; 2022; 12():863609. PubMed ID: 35494057
[TBL] [Abstract][Full Text] [Related]
32. Multiple Site SBRT in Pediatric, Adolescent, and Young Adult Patients With Recurrent and/or Metastatic Sarcoma.
Parsai S; Sedor G; Smile TD; Scott J; Ochocki A; Vassil N; Zahler S; Angelov L; Chao ST; Qi P; Anderson P; Murphy ES
Am J Clin Oncol; 2021 Mar; 44(3):126-130. PubMed ID: 33405479
[TBL] [Abstract][Full Text] [Related]
33. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
[TBL] [Abstract][Full Text] [Related]
34. Retrospective analysis of stereotactic ablative radiotherapy (SABR) for metastatic lung lesions (MLLs) in comparison with a contemporaneous cohort of primary lung lesions (PLLs).
Oskan F; Dzierma Y; Wagenpfeil S; Rübe C; Fleckenstein J
J Thorac Dis; 2017 Mar; 9(3):742-756. PubMed ID: 28449482
[TBL] [Abstract][Full Text] [Related]
35. Stereotactic Body Radiotherapy for Lung Metastases from Colorectal Cancer: Prognostic Factors for Disease Control and Survival.
Qiu H; Katz AW; Chowdhry AK; Usuki KY; Singh DP; Metcalfe S; Cheruvu P; Chen Y; Okunieff P; Milano MT
Am J Clin Oncol; 2018 Jan; 41(1):53-58. PubMed ID: 26270442
[TBL] [Abstract][Full Text] [Related]
36. Predictors of Early Polymetastatic Relapse After SABR for up to 5 Oligometastases: A Secondary Analysis of the Phase II SABR-5 Trial.
Baker S; Mou B; Jiang W; Liu M; Bergman AM; Schellenberg D; Alexander AS; Carolan H; Atrchian S; Berrang T; Bang A; Chng N; Matthews Q; Tyldesley S; Olson RA
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):856-861. PubMed ID: 35840110
[TBL] [Abstract][Full Text] [Related]
37. Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy.
Binkley MS; Trakul N; Jacobs LR; von Eyben R; Le QT; Maxim PG; Loo BW; Shultz DB; Diehn M
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1044-1052. PubMed ID: 26025776
[TBL] [Abstract][Full Text] [Related]
38. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
[TBL] [Abstract][Full Text] [Related]
39. Stereotactic Ablative Radiation Therapy for Pulmonary Metastases: Histology, Dose, and Indication Matter.
Helou J; Thibault I; Poon I; Chiang A; Jain S; Soliman H; Erler D; Yeung L; Cheung P
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):419-427. PubMed ID: 28463162
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic ablative radiotherapy as single treatment for early stage non-small cell lung cancer: A single institution analysis.
Zheng X; Sun Y; Ye K; Fan C; Wang X; Yang Y; Jiao R; Ge H
Thorac Cancer; 2021 Mar; 12(6):899-905. PubMed ID: 33529496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
